Effectiveness of golimumab in rheumatoid arthritis patients with inadequate response to first-line biologic therapy: Results from a Japanese post-marketing surveillance study. Issue 3 (4th May 2021)

• Record Type: Journal Article
• Authors: Shimizu, Hirohito; Kobayashi, Hisanori; Kanbori, Masayoshi; Ishii, Yutaka
• Is Part Of: Modern rheumatology. Volume 31:Issue 3(2021)
• Page Start: 556
• Page End: 565
• Publication Date: 2021-05-04
• Subjects: Biological disease-modifying antirheumatic drugs -- golimumab -- real-wolrd evidence -- rheumatoid arthritis -- switching; Rheumatology -- Periodicals; 616.723005
• DOI: 10.1080/14397595.2020.1797266
• Languages: English
• ISSNs: 1439-7595

Abstract

Abstract: Objectives: To assess the real-world effectiveness of golimumab in Japanese patients with rheumatoid arthritis who had previously received first-line biologic therapy. Methods: A post-hoc analysis of post-marketing surveillance was performed. The effectiveness of golimumab was assessed in 731 patients with an inadequate response to first-line biologic therapy stratified by their prior biologic agents. Outcome variables included DAS28-CRP, DAS28-ESR, SDAI and CDAI, and medication persistence. Logistic regression analyses were conducted to identify factors associated with the likelihood of achieving a DAS28-CRP response (good/moderate) after 24 weeks of golimumab treatment. Results: Patients demonstrated significant improvement in the clinical signs and symptoms of rheumatoid arthritis at 24 weeks, as indicated by the reduction of DAS28-CRP (Δ0.87), DAS28-ESR (Δ0.85), SDAI (Δ7.32), and CDAI (Δ6.98) scores. This result was consistent across the subgroups stratified by previous biologic therapy. Multivariate analysis failed to identify any factors associated with response to golimumab. Conclusion: In the real-world clinical setting, switching to golimumab was effective for Japanese patients with an inadequate response to first-line biologic therapy regardless of the biologic agent, including both TNF and non-TNF inhibitors.